Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on notice
Regeneron pens $2.3B pact with Parabilis to develop new type of ADC-like therapy
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals

Unlocking MUC1-C for ADC Therapy: Translational Innovation of XYA01/02 from Preclinical Validation to Clinical Forefront

By | 8 June 2026

Contextualizing suboptimal MUC1-N targeting properties to demonstrate benefits to MUC1-C subunit as an ADC target
Exploring preclinical PDX safety and efficacy for XYA01/02 leading to NCI NExT program selection and IND enabling development
Evaluating XYA01/02 trial design positioning for differentiated impact across MUC1-C-expressing epithelial carcinomas versus existing anti-MUC1 ADCs